Sodium orthovanadate overcomes sorafenib resistance of hepatocellular carcinoma cells by inhibiting Na(+)/K(+)-ATPase activity and hypoxia-inducible pathways

The resistance to sorafenib highly affects its clinical benefits for treating hepatocellular carcinoma (HCC). Sodium orthovanadate (SOV) is a phosphate analog that displays anti-cancer activities against various types of malignancies including HCC. The present study has demonstrated that SOV is able...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Wenjing, Li, Guangxin, Li, Weidong, Wang, Ping, Xiu, Peng, Jiang, Xian, Liu, Bing, Sun, Xueying, Jiang, Hongchi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018801/
https://www.ncbi.nlm.nih.gov/pubmed/29946188
http://dx.doi.org/10.1038/s41598-018-28010-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018801/
https://www.ncbi.nlm.nih.gov/pubmed/29946188
http://dx.doi.org/10.1038/s41598-018-28010-y

Ejemplares similares